TNC anticorps
-
- Antigène Voir toutes TNC Anticorps
- TNC (Tenascin C (TNC))
-
Reactivité
- Humain, Cobaye, Lapin
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp TNC est non-conjugé
-
Application
- Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)
- Specificité
- The antibody clone EB2 reacts with the 4th and 5th fibronectin-like repeats of Human Tenascin-C polypeptides of Mr 250000 and 180000.
- Réactivité croisée (Details)
- Species reactivity (tested):Human, Guinea Pig and Rabbit.
- Purification
- Ig Fraction
- Immunogène
- Purified Tenascin-C from human fetal fibroblasts. Hybridoma produced by fusion between myeloma cells and Balb/c spleen cells.
- Clone
- EB2
- Isotype
- IgG1
- Top Product
- Discover our top product TNC Anticorps primaire
-
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Concentration
- 0.1 mg/mL
- Buffer
- PBS, 0.09 % Sodium Azide, 1.0 % BSA
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C
- Stockage commentaire
- Store the antibody undiluted at 2-8 °C.
-
- Antigène
- TNC (Tenascin C (TNC))
- Autre désignation
- Tenascin / TNC / HXB (TNC Produits)
- Synonymes
- anticorps tn, anticorps 150-225, anticorps GMEM, anticorps GP, anticorps HXB, anticorps JI, anticorps TN, anticorps TN-C, anticorps AI528729, anticorps C130033P17Rik, anticorps Hxb, anticorps Ten, anticorps cytotactin, anticorps tenascin-C, anticorps P230, anticorps tenc, anticorps wu:fk04d02, anticorps tenascin C L homeolog, anticorps tenascin C, anticorps tnc.L, anticorps TNC, anticorps MCYG_00667, anticorps tnc, anticorps Tnc
- Sujet
- Tenascins were first characterized in the early 1980's. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology. The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma.Synonyms: Cytotactin, GMEM, GP 150-225, Glioma-associated-extracellular matrix antigen, Hexabrachion, Myotendinous antigen, Neuronectin, TN-C, Tenascin-C
- ID gène
- 3371
- NCBI Accession
- NP_002151
- UniProt
- P24821
- Pathways
- Regulation of Muscle Cell Differentiation, Regulation of Cell Size, Skeletal Muscle Fiber Development
-